Tissue protection by erythropoietin: New findings in a moving field

Kidney International

Volumn 84, Issue 3, 2013, Pages 427-429

  Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HETERODIMER; HOMODIMER; KLOTHO PROTEIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ACUTE KIDNEY FAILURE; ANEMIA; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CYTOTOXICITY; ERYTHROPOIESIS; HUMAN; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REVIEW;

ACUTE KIDNEY INJURY; ANIMALS; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; CYTOPROTECTION; ERYTHROPOIETIN; GLUCURONIDASE; HUMANS; KIDNEY; MALE; RECEPTORS, ERYTHROPOIETIN; SEPSIS;

EID: 84883317563     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.140     Document Type: Note

References (14)

1. Asada N, Takase M, Nakamura J et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011; 121: 3981-3990.
2. Chiang CK, Tanaka T, Inagi R et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011; 91: 1564-1571.
3. Yang WS, Chang JW, Han NJ et al. Darbepoetin alpha suppresses tumor necrosis factor-alphainduced endothelin-1 production through antioxidant action in human aortic endothelial cells: Role of sialic acid residues. Free Radic Biol Med 2011; 50: 1242-1251.
4. Eto N, Wada T, Inagi R et al. Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72: 455-463.
5. Hu M-C, Shi M, Cho HJ et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int 2013; 84: 468-481.
6. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-1895.
7. Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010; 115: 4264-4272.
8. Coldewey SM, Khan AI, Kapoor A et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the b-common receptor. Kidney Int 2013; 84: 482-490.
9. Hand CC, Brines M. Promises and pitfalls in erythropoietin-mediated tissue protection: Are nonerythropoietic derivatives a way forward? J Investig Med 2011; 59: 1073-1082.
10. Su KH, Shyue SK, Kou YR et al. b Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011; 226: 3330-3339.
11. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121: 4210-4221.
12. Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 2012; 318: 11068-11073.
13. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alpha in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
14. Corwin HL, Gettinger A, Fabian TC et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976.